CompletedPhase 1
A phase 1, open-label trial in healthy subjects and in subjects with diabetes investigating pharmacokinetics, tolerability, safety, and food effect following single and multiple dosing of danegaptide
Key facts
- Where
- Uppsala, SwedenSee the site
- Phase
- Phase 1
Where in Sweden
- CTC Clinical Trial Consultants ABUppsala, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Breye Therapeutics ApS
- Trial code
- EU 2024-515078-28-00
- Record updated
- 11 August 2025